Eli Lilly is acquiring Merida Biosciences for up to $2.9 billion, adding a platform designed to attack autoimmune disease precisely: by hunting down and destroying the specific malfunctioning antibodies that cause it, while leaving normal immunity intact.

The trade-off in current autoimmune treatment

Autoimmune diseases occur when the immune system attacks the body’s own tissue, frequently through autoantibodies — antibodies directed at self.

Almost every available treatment works by turning the immune system down. Steroids, conventional immunosuppressants, biologics blocking inflammatory cytokines, B-cell-depleting antibodies: all reduce autoimmune damage by reducing immune function generally.

The cost is inherent to the approach. A suppressed immune system fights infection less well and performs surveillance against cancer less effectively. Patients accept elevated infection risk, sometimes serious, and take on long-term monitoring — a permanent bargain rather than a temporary one.

What selectivity would mean

Merida’s approach tags pathogenic autoantibodies for destruction, targeting the specific disease-causing molecules rather than the cells that produce them or the inflammatory response they provoke.

The distinction is meaningful. B-cell depletion removes the factories — including the ones producing the antibodies that fight infection. Removing only the pathogenic antibody product leaves the rest of humoral immunity operating.

“We’re building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects,” said Lilly immunology research head Francisco Ramírez-Valle.

Why Graves’ disease is the right first target

The lead programme, MER511, targets the autoantibodies behind Graves’ disease and thyroid eye disease, and entered Phase 1 in late 2025.

Graves’ is close to an ideal proof of concept. It has an unusually clean mechanism: autoantibodies bind and activate the receptor for thyroid-stimulating hormone, driving the thyroid to overproduce hormone continuously. The disease is essentially caused by one identifiable antibody doing one identifiable thing.

Thyroid eye disease is the associated complication in which tissue behind the eye becomes inflamed and expands, pushing the eye forward — disfiguring, sometimes threatening vision, and notably difficult to treat.

Critically, existing Graves’ treatments do not directly target those autoantibodies. Current management suppresses hormone production, destroys thyroid tissue with radioactive iodine, or removes the gland surgically — all of which address the consequence while leaving the autoimmune driver untouched, usually committing patients to lifelong hormone replacement.

Lilly’s immunology spree

This is Lilly’s third immunology acquisition of 2026, among a dozen deals that year — more than any peer — funded in part by windfall profits from its obesity drugs Zepbound and Mounjaro.

The strategic logic is straightforward. Extraordinary obesity revenue creates both the capital and the need to diversify: a company overwhelmingly dependent on one therapeutic area faces real risk when competition or pricing pressure arrives. Immunology is a large, durable market with substantial unmet need, and buying into it early is cheaper than buying clinical-stage assets later.

How early this is

Merida launched only in April 2025 with $121 million in venture funding. Roughly eighteen months later it is being acquired for up to $2.9 billion, with its lead programme in Phase 1.

That trajectory says as much about the market as about the science. Competition for differentiated autoimmune platforms has become intense enough that large pharmaceutical companies are buying before human efficacy data exists, accepting substantial risk to avoid being outbid later.

The deal is expected to close by the end of 2026.

What has to be proven

The central question is whether selective autoantibody destruction works well enough in practice. Autoantibody levels correlate imperfectly with disease activity in many conditions, and reducing them is not automatically the same as controlling disease.

Durability is the second issue. Removing circulating antibodies does not remove the plasma cells producing them, so unless the underlying autoimmune process is interrupted, antibodies would be expected to return — implying chronic repeat dosing rather than a cure.

And the selectivity claim itself must survive contact with humans. Distinguishing pathogenic autoantibodies from the vast repertoire of protective ones is demanding, and any cross-reactivity would erode the entire advantage over broad immunosuppression.

Why the strategy is attractive regardless

Autoimmune disease affects large numbers of people, often from young adulthood, and the current bargain — controlling the disease by accepting a compromised immune system for life — is genuinely unsatisfactory.

Where else the platform could go

Graves’ disease is the entry point rather than the prize, and the reason a platform commands this valuation is what sits behind it.

A number of autoimmune conditions are driven by identifiable autoantibodies with well-understood targets. Myasthenia gravis involves antibodies against the receptor that transmits nerve signals to muscle. Certain kidney and blistering skin diseases are driven by antibodies against specific structural proteins. Several neurological syndromes are caused by antibodies against particular neuronal receptors. In each case the pathogenic molecule is known.

Any platform that can be pointed at one identified autoantibody can in principle be pointed at another, with the target-specific component swapped and the underlying destruction machinery retained. That is the difference between buying a drug and buying a platform — and it is why an acquirer pays for a preclinical asset rather than waiting to license a proven one.

Any approach that removes the cause while leaving normal immunity intact addresses that directly. It is the same intuition driving investment in precise B-cell targeting elsewhere in the industry, approached from a different angle: destroy the product rather than the producer. Business news, not investment advice.